TP-04 is under clinical development by Tarsus Pharmaceuticals and currently in Phase I for Rosacea. According to GlobalData, Phase I drugs for Rosacea have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TP-04’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TP-04 is under development for the treatment of rosacea.
Tarsus Pharmaceuticals overview
Tarsus Pharmaceuticals is a biopharmaceutical company that is involved in development and commercialization of therapeutics related to eye care. It is developing novel therapeutics for treatment of blepharitis which is caused by the infestation of Demodex mites. The company having the product pipeline for Meibomian Gland Disease, Rosacea, Lyme Disease and Malaria. The company is headquartered in Irvine, California, the US.
For a complete picture of TP-04’s drug-specific PTSR and LoA scores, buy the report here.